CRTX - Cortexyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.64
-3.98 (-6.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close62.62
Open63.29
Bid57.00 x 1800
Ask65.00 x 1800
Day's Range56.94 - 65.03
52 Week Range19.35 - 72.94
Volume114,440
Avg. Volume179,562
Market Cap1.575B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.40
  • Business Wire

    Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s Disease

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease (AD). Additionally, the GAIN Trial Data Monitoring Committee recently completed its first planned safety review and recommended continuation of the study as planned.

  • Business Wire

    Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.

  • Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • American City Business Journals

    Last year's Bay Area IPO performances show why it pays to be an insider

    Timing is everything: Here's a look at the big gap in returns for public and private investors in the best performing new Bay Area stocks from last year.

  • Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber
    Zacks

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

  • 5 Hottest IPOs of 2019
    Zacks

    5 Hottest IPOs of 2019

    2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Business Wire

    Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease

    Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the "gingipain hypothesis" for Alzheimer’s disease (AD) to the significance of the APOE gene as a major risk factor for the disease. Michael Detke, M.D., Ph.D., the company’s chief medical officer, detailed the results in an oral presentation (abstract OC28) at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD) meeting, which is being held December 4-7, 2019 in San Diego.

  • MarketWatch

    Biogen's shares drop on critical view of Alzheimer's data

    Biogen shares fell 2.6% after an analyst scoffed at the possibility of a Food and Drug Administration approval for the company's experimental Alzheimer's disease treatment. "There are so many reasons we think aducanumab is getting rejected, our word count restrictions don't allow us to put them all here," Baird analyst Brian Skorney wrote in a Dec. 2 note. Skorney's primary argument is that he believes data from the most recent clinical trial doesn't make for a compelling case to take to the FDA. Earlier this year, Biogen's stock tumbled to a three-year low after the company said it would stop trials for the therapy, prompting Mizuho analyst Salim Syed to say "aducanumab is dead, and we'd argue so is the beta-amyloid hypothesis." But then in October Biogen announced plans to pursue FDA approval following discussions with the regulator. The biopharmaceutical company has said it will release additional clinical trial information about aducanumab on Dec. 5. Separately, shares of Cortexyme Inc. , which is also developing an Alzheimer's treatment, jumped in morning trading, by 20%. Shares of Biogen have fallen about 3% year-to-date, compared to the S&P 500 , which has gained about 24%.

  • Business Wire

    Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 2:00 p.m. EST / 11:00 a.m. PST in Boston.

  • Business Wire

    Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3 GAIN clinical trial

  • The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
    Zacks

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

  • 4 Best-Performing IPOs So Far in 2019
    Zacks

    4 Best-Performing IPOs So Far in 2019

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

  • Business Wire

    Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019

    Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch briefing on the preclinical and clinical data supporting COR388’s mechanism of action, as well as its evaluation in the ongoing Phase 2/3 GAIN trial.

  • Top Ranked Momentum Stocks to Buy for October 9th
    Zacks

    Top Ranked Momentum Stocks to Buy for October 9th

    Top Ranked Momentum Stocks to Buy for October 9th

  • Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Top Ranked Momentum Stocks to Buy for September 23rd
    Zacks

    Top Ranked Momentum Stocks to Buy for September 23rd

    Top Ranked Momentum Stocks to Buy for September 23rd

  • What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?

    The big shareholder groups in Cortexyme, Inc. (NASDAQ:CRTX) have power over the company. Generally speaking, as a...